{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Embecta Corp. Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Embecta Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum. While its daily moving averages show positive short-term trends, the stock's performance over the past year and year-to-date reveals significant underperformance compared to the S&P 500, warranting careful observation of future developments.
Embecta Corp. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Embecta Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, is currently priced at $13.90, with a 52-week range of $9.20 to $21.48. The stock has faced significant challenges, underperforming against the S&P 500, with year-to-date returns of -32.69% compared to the index's gains.
Is Embecta Corp. technically bullish or bearish?
As of September 26, 2025, Embecta Corp. shows a neutral trend with mixed signals, including a mildly bearish daily moving average and a year-to-date return of -32.69%, significantly underperforming the S&P 500's 12.96%.
Is Embecta Corp. technically bullish or bearish?
As of September 26, 2025, Embecta Corp. shows a neutral trend with mixed signals, as the weekly MACD is bullish while daily moving averages are mildly bearish, and it has underperformed the S&P 500 significantly with a year-to-date return of -32.69%.
Is Embecta Corp. technically bullish or bearish?
As of September 26, 2025, Embecta Corp. shows a neutral technical trend with mixed signals, including a mildly bearish daily moving average and a year-to-date return of -32.69%, significantly underperforming the S&P 500's 12.96%.
Is Embecta Corp. technically bullish or bearish?
As of September 4, 2025, Embecta Corp. shows a mildly bullish trend supported by weekly and monthly indicators, despite mixed short-term signals and significant underperformance compared to the S&P 500.
Embecta Corp. Reports Strong Financial Results with Record Profit and Cash Flow in June 2025
Embecta Corp. reported strong financial results for the quarter ending June 2025, with significant increases in pre-tax profit and net profit. The company achieved its highest interest coverage ratio in five periods and improved operating cash flow. However, a decline in the debtors turnover ratio may require attention.
Is Embecta Corp. overvalued or undervalued?
As of May 13, 2022, Embecta Corp. is considered undervalued with a low P/E ratio of 6 and a high ROCE of 38.19%, despite its stock underperforming the S&P 500 by -52.45% year-to-date, indicating a shift to a risky valuation grade.
Is Embecta Corp. technically bullish or bearish?
As of May 22, 2025, Embecta Corp. is in a bearish trend, supported by negative signals from MACD, moving averages, and Dow Theory, indicating a continued weakness in its performance.
What does Embecta Corp. do?
Embecta Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $259 million and a net profit of $24 million. It has a market cap of $575.07 million, a P/E ratio of 6.00, and a dividend yield of 3.03%.
How big is Embecta Corp.?
As of Jun 18, Embecta Corp. has a market capitalization of 575.07 million and reported net sales of 1,079.50 million with a net profit of 52.80 million over the last four quarters. As of Sep 24, shareholder's funds were -738.30 million, and total assets amounted to 1,285.30 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
